"This license from the prestigious Weizmann Institute of Science represents an exciting opportunity for PROLOR," said Dr. Phillip Frost, Chairman of PROLOR.  "It complements our core platform and expands our pipeline of competitive long-acting therapeutic drug candidates to include new, important clinical indications."

Oxyntomodulin is a naturally occurring peptide hormone released by the digestive system following food ingestion that acts as a natural satiety signal to reduce food intake and increase energy expenditure.  Previous third party studies in humans have demonstrated the potential of oxyntomodulin to reduce appetite and food intake, leading to significant weight loss without side effects.  However, oxyntomodulin must be administered by subcutaneous injection and its short half-life may require frequent dosing.  PROLOR's long-acting oxyntomodulin, which is expected to have  a more favorable dosing profile, is currently in preclinical development.

SOURCE PROLOR Biotech, Inc.